Bujan-Rivas Segundo, Basagaña Maria, Sena Francisca, Méndez Maria, Dordal Maria Teresa, Gonzalez-Roca Eva, Ruiz-Ortiz Estibaliz, Mensa-Vilaró Anna, Plaza Susana, Modesto Consuelo, Ordi-Ros Josep, Yagüe Jordi, Martínez-Valle Ferrán, Aróstegui Juan Ignacio
Department of Internal Medicine, Hospital Vall Hebron, Barcelona, Spain.
Department of Allergy, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):27-31. Epub 2017 Jan 9.
Cryopyrin-associated periodic syndromes (CAPS) usually start during infancy as an urticarial-like rash and a marked acute phase response, with additional manifestations appearing during its evolution. The aim of this study was to expand the clinical diversity of CAPS by the description of novel atypical features.
Clinical data were collected from patients' medical charts. Sanger sequencing analyzed NLRP3. Response to anti-IL-1 blockade was evaluated by clinical assessments and by measurements of laboratory parameters.
Seventeen patients from two families (A and B), carrying the p.Ala439Thr and p.Arg260Trp NLRP3 mutations respectively, were enrolled. The disease was unexpectedly atypical in all members of Family A, with a 16-year-old asymptomatic carrier, and onset in adulthood associated with absence of skin lesions in four affected members. Surprisingly, one patient from each family suffered from severe haemorrhagic cystitis due to AA amyloidosis in the urinary bladder. Members of Family B displayed a classical phenotype, with two patients suffering from olfactive disorders.
Our evidence suggests that CAPS may occasionally be presented as a late-onset, recurrent inflammatory disease without urticarial-like rash. In some patients, AA amyloidosis in strange locations like urinary bladder may complicate the clinical course. The response to IL-1 blockade in these atypical CAPS was similar to that described in classical forms. Consequently, we suggest that CAPS should be included in the differential diagnosis of adult patients with unexplained, recurrent inflammatory diseases, and once confirmed, the early initiation of anti-IL-1 blockade will probably prevent the development of life-threatening complications.
冷吡啉相关周期性综合征(CAPS)通常在婴儿期开始,表现为荨麻疹样皮疹和明显的急性期反应,并在疾病进展过程中出现其他表现。本研究旨在通过描述新的非典型特征来扩展CAPS的临床多样性。
从患者病历中收集临床数据。采用桑格测序法分析NLRP3。通过临床评估和实验室参数测量评估抗IL-1阻断治疗的反应。
招募了来自两个家族(A和B)的17名患者,分别携带p.Ala439Thr和p.Arg260Trp NLRP3突变。A家族所有成员的疾病均出人意料地不典型,有一名16岁的无症状携带者,四名受影响成员在成年期发病且无皮肤病变。令人惊讶的是,每个家族各有一名患者因膀胱AA淀粉样变性而患有严重的出血性膀胱炎。B家族成员表现出典型的表型,有两名患者患有嗅觉障碍。
我们的证据表明,CAPS偶尔可能表现为迟发性复发性炎症性疾病,无荨麻疹样皮疹。在一些患者中,膀胱等不寻常部位的AA淀粉样变性可能使临床病程复杂化。这些非典型CAPS对抗IL-1阻断治疗的反应与经典形式中描述的相似。因此,我们建议CAPS应纳入成年不明原因复发性炎症性疾病患者的鉴别诊断中,一旦确诊,尽早开始抗IL-1阻断治疗可能会预防危及生命的并发症的发生。